ACE Pharmaceuticals BV   Report issue

For profit Phase 3
Founded: Zeewolde Netherlands (1990)
Status: No NME R&D (1990)

Organization Overview

First Clinical Trial
2017
NCT03162653
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

ACE Pharmaceuticals BV

Active Ingredients

Drugs in Phase 3 Trials (3)

allopurinol (zyloprim) (2 trials)

liothyronine (cytomel) (1 trial)

mannitol (Osmitrol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 3)

Brain Injuries (Phase 3)

Heart Defects, Congenital (Phase 3)

Heart Diseases (Phase 3)

Hypoxia (Phase 3)

Hypoxia, Brain (Phase 3)

Hypoxia-Ischemia, Brain (Phase 3)

Infant, Newborn, Diseases (Phase 3)

Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3